Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper Sells 1,949 Shares of Stock

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now owns 177,195 shares in the company, valued at approximately $5,315,850. This represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Collegium Pharmaceutical Stock Up 2.6 %

COLL stock opened at $29.66 on Tuesday. The company has a market cap of $933.87 million, a P/E ratio of 12.78 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 52 week low of $27.28 and a 52 week high of $42.29. The company’s 50-day moving average price is $30.80 and its 200 day moving average price is $33.15. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the stock. New Age Alpha Advisors LLC purchased a new stake in Collegium Pharmaceutical during the fourth quarter worth about $40,000. TD Private Client Wealth LLC lifted its holdings in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Collegium Pharmaceutical in the third quarter valued at about $72,000. KBC Group NV lifted its holdings in shares of Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after purchasing an additional 982 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares in the last quarter.

Analysts Set New Price Targets

COLL has been the topic of a number of recent analyst reports. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. Finally, Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.